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In Western countries the incidence of the esophageal adenocarcinoma (EAC) has risen at a
more rapid rate than that of any other malignancy. Despite intensive therapies this cancer
is associated with extreme high morbidity and mortality. For this reason, novel effective
therapeutic strategies are urgently required. Dendritic Cell (DC)-based immunotherapy is a
promising novel treatment strategy, which combined with other anti-cancer strategies has
been proven to be beneficial for cancer patients. Curcumin (diferuloylmethane), is a natural
polyphenol that is known for its anti-cancer effects however, in it’s free form, curcumin has
poor bioavailability.The aim of this study was to investigate whether using a highly absorp-
tive form of curcumin, dispersed with colloidal nano-particles, named Theracurmin would
be more effective against EAC cells and to analyze if this new compound affects DC-induced
T cell response. As a result, we show efficient uptake of nano-curcumin by the EAC cell
lines, OE33, and OE19. Moreover, nano-curcumin significantly decreased the proliferation
of the EAC cells, while did not affect the normal esophageal cell line HET-1A. We also found
that nano-curcumin significantly up-regulated the expression of the co-stimulatory mole-
cule CD86 in DCs and significantly decreased the secretion of pro-inflammatory cytokines
from in vitro activated T cells. When we combined T cells with nano-curcumin treatment
in OE19 and OE33, we found that the basic levels of T cell induced cytotoxicity of 6.4 and
4.1%, increased to 15 and 13%, respectively. In conclusion, we found that nano-curcumin is
effective against EAC, sensitizes EAC cells toT cell induced cytotoxicity and decreases the
pro-inflammatory signals from T cells. Combining DC immunotherapy with nano-curcumin
is potentially a promising approach for future treatment of EAC.
Keywords: curcumin, nano-curcumin, theracurmin, esophageal adenocarcinoma, dendritic cell vaccines,
T cell responses
INTRODUCTION
Esophageal adenocarcinoma (EAC) has the most rapidly increas-
ing incidence compared to other malignancies (Gamliel, 2000;
Brown et al., 2008). Overall EAC patients have a rather poor prog-
nosis with a 5-year survival rate of <15% (Gee and Rattner, 2007;
Shimada et al., 2008). Therefore, more effective treatments are
urgently required. Recently, Dendritic Cell (DC)-based therapeu-
tic cancer vaccines have proven to be a promising therapy for
the treatment of cancer. For the preparation of DC-based cancer
vaccines, DCs are loaded ex vivo with tumor antigens, and then
given back to patients. After activation by the DCs, T cells become
effector cytotoxic T lymphocytes (CTLs), which can recognize
and lyse tumor cells (Boczkowski et al., 1996; Nair et al., 1998;
Milano et al., 2007). Despite the promising advances in DC vacci-
nation, the outcomes of patients treated with DC immunotherapy
as a monotherapy are still below expectations and several critical
hurdles have to be resolved to improve its effectiveness (Fox et al.,
2011). It has been shown that an unfavorable tumor microenvi-
ronment, that inhibits the development and function of DCs and
CTLs, plays a major role in this phenomenon (Zou, 2005, 2006).
It has become clear that using DC-based therapeutic vaccines in
combination with agents that modulate the tumor microenviron-
ment, sensitize the tumor cells, or diminish the tumor bulk prior to
DC treatment, would highly enhance the efficacy of this approach
(Milano and Krishnadath, 2008; Kamrava et al., 2009; Dougan
et al., 2010). Therefore, it is necessary to find new combinatorial
approaches, which tilt the balance in favor of tumor immunity
and enhance DC-induced T cell response in cancer patients. In
this respect, the natural substance Curcumin 1,6-Heptadiene-3,5-
dione, 1,7-bis(4-hydroxy-3-methoxyphenyl), (1E,6E)-, a derivate
of the plantCurcuma longa, has recently gained interest. Curcumin
is known to have beneficial effects against several types of cancers,
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such as colon, colorectal, pancreatic, and esophageal cancer (Kun-
numakkara et al., 2009; O’Sullivan-Coyne et al., 2009; Sahu et al.,
2009; Sandur et al., 2009; Jutooru et al., 2010). Several studies
have shown that curcumin can suppress nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB) activation. Up-
regulation of NF-κB is known to be a key event for carcinogenesis.
Curcumin also down regulates the expression of NF-κB regulated
gene products that play a role in anti-apoptosis, proliferation,
invasion, angiogenesis, and metastasis (Singh and Aggarwal, 1995;
Aggarwal et al., 2006; Rafiee et al., 2009; Hartojo et al., 2010).
Furthermore, curcumin can down-regulate the expression of var-
ious pro-inflammatory cytokines such as TNF-α, IL-1, IL-2, IL-8,
IL-12 (Xu et al., 1997; Hidaka et al., 2002; Kunnumakkara et al.,
2009; Epstein et al., 2010). Importantly, it sensitizes pancreatic
tumor cells to the chemotherapeutic drug Gemcitabine, by sup-
pressing proliferation and angiogenesis (Kanai et al., 2010). In
addition, curcumin has been proven to be remarkably safe in ani-
mal studies and in phase I/II clinical trials even in dosages as high
as 12 g per day (Shankar et al., 1980; Sharma et al., 2004; Lao
et al., 2006; Dhillon et al., 2008). Curcumin is classified “gen-
erally recognized as safe” (GRAS) by the US Food and Drug
Administration. In spite of all the proven beneficial effects of
curcumin, the major problem limiting the effect in patients, is
its poor solubility in water and consequently poor bioavailability
(Anand et al., 2007; Yang et al., 2007). In the present study, an
effective preparation of curcumin, a nano-particle colloidal dis-
persion, with highly improved bioavailability and water solubility,
named Theracurmin, was used (Sasaki et al., 2011). This com-
pounds is composed of 10% curcumin, 2% other curcuminoids
(demethoxycurcumin and bisdemethoxycurcumin), 46% glycerin,
4% gum ghatti, and 38% water. Because of a superior solubility
in water, Theracurmin allows easier in vitro testing, and eventual
in vivo administration as compared to free curcumin (Bisht et al.,
2007; Anand et al., 2010). In this study, we first evaluated the
direct effects of Theracurmin (nano-curcumin) on EAC cell lines.
Secondly, we evaluated the direct effects of nano-curcumin on acti-
vated T cells and DCs. Finally, we tested whether nano-curcumin
would sensitize the tumor cells to DC-mediated cytotoxic T cell
response and would more effectively induce lysis of esophageal
cancer cells.
MATERIALS AND METHODS
CELL CULTURE
OE19 and OE33 esophageal Barrett cancer cell lines were
purchased from ECACC (Porton Down, Wiltshire, SP4 DJG,
UK), and cultured in RPMI 1640 (Invitrogen, NY, USA)
supplemented with 10% fetal calf serum (FCS) (Invitro-
gen), 100 U/ml penicillin (Invitrogen), 100µg/ml streptomycin
(Invitrogen), and 2 mmol/l l-glutamine (Invitrogen). HET-1A
esophageal squamous cells were purchased from the American
Type Culture Collection (Manassas, VA, USA), and cultured
in MCDB-153 medium (Sigma, St. Louis, MO, USA) mod-
ified as previously described (Milano et al., 2007). All cells
were cultured in a 5% CO2 incubator at 37 °C. The cells
were maintained with twice weekly passage/refreshing medium
and were harvested with trypsin-ethylenediamine tetra-acetic
acid (EDTA).
CELL TREATMENT WITH NANO-CURCUMIN
Nano-curcumin (Theracurmin) was a kind gift by S. Guha (MD
Anderson Cancer Center, Huston, TX, USA), and was provided
by Theravalues Corporation (Tokyo, Japan). Nano-curcumin was
dissolved in sterile water. After establishing the IC50 using MTS
assay (data not shown), the final concentration of 50µM nano-
curcumin at the time point of 48 h was chosen. For the experi-
ments, cells were either left untreated or exposed to 50µM nano-
curcumin for 48 h and subsequently harvested for different types
of analysis.
BrdU ASSAY FOR MEASUREMENT OF CELL PROLIFERATION
To measure cell proliferation, OE19, OE33, and HET-1A cells were
plated in quadruplicate in a black 96 well microplate. After treat-
ment with nano-curcumin, cell proliferation was measured using
a BrdU incorporation assay (Roche, Almere, The Netherlands).
Briefly, cells were labeled with 10µM BrdU for 4 h at 37 °C and
the labeling solution was subsequently removed. The cells were
fixed and the DNA was denatured by adding FixDenat solution for
30 min at room temperature, then the anti-BrdU POD antibody
was added and the plate was incubated for 90 min at RT. Next,
the plate was washed 3 times and the developing substrate was
added and incubated for 3 min. Finally, chemiluminescence was
measured using a Synergy multi-mode microplate reader (BioTek
Instruments, Winooski, VT, USA). Supernatants were collected
and used to measure the effect of nano-curcumin on the cytokine
production of the different cell lines by performing CBA (see
description below).
WESTERN BLOT ANALYSIS
The expression of caspase-3 and procaspase-9 was detected using
Western blot. After treatment with nano-curcumin, OE19, OE33,
and HET-1A cells were harvested in M-PER mammalian protein
extraction reagent (Thermo Scientific, Rockford, USA) and the
protein concentration was determined using a BCA assay (Thermo
Scientific, Rockford, USA). Equal concentrations (25µg) of pro-
teins were fractionated by SDS-polyacrylamide gel electrophoresis,
electro-transferred to Polyvinylidene fluoride (PVDF) membranes
and blocked in 5% low fat milk in TBST. For the detection of
caspase-3 and caspase-9, membranes were probed using primary
anti-human rabbit polyclonal caspase-3 antibody (Abcam, Cam-
bridge, UK, ab90437) or primary anti-human rabbit polyclonal
caspase-9 antibody (Santa Cruz, CA, USA, 556585). Blots were
then washed with TBST and incubated for 1 h at room temperature
in 1:1000 Horse Radish Peroxidase (HRP) conjugated secondary
antibody in 5% low fat milk in TBST. After a final wash with TBST,
blots were incubated for 5 min in Lumilight (Roche, Almere, The
Netherlands) and chemiluminescence was detected using a Image-
Quant LAS 4000 biomolecular imager (GE Healthcare). Band
intensity from electronic images of western blots was calculated
by densitometry using the public domain Java image processing
program Image J (available at http://rsb.info.nih.gov/ij; developed
by Wayne Rasband, National Institutes of Health, Bethesda, MD).
FLUORESCENCE MICROSCOPY FOR NANO-CURCUMIN UPTAKE IN EAC
CELLS
Curcumin is naturally fluorescent in the visible green spectrum
(Bisht et al., 2007). In order to study intracellular uptake of
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nano-curcumin, the cells were plated in an 8-well culture glass slide
(BD Biosciences), and allowed to grow to sub-confluent levels.
Thereafter, the cells were incubated with 50µM nano-curcumin
for different time points ranging from 0 to 48 h. The slides were
mounted in Vectashield Mounting Medium (Vector laboratories)
with DAPI (4′, 6-diamidino-2-phenylindole) in order to visual-
ize the nucleus of the cells and visualized in the Green channel
using confocal laser scanning microscope (CLSM) coupled to an
inverted microscope (Olympus IX81, Japan).
RNA ISOLATION
RNA of the different esophageal cell lines was isolated using the
RNeasy mini kit (Qiagen, Hilden, Germany). Briefly, the cells
were disrupted in RLT buffer and homogenized, ethanol was
added and the mixture was applied to an RNeasy mini spin col-
umn. Total RNA bonded to the membrane while contaminants
were washed away using buffer RW1 and buffer RPE, containing
ethanol. Finally, the total RNA was eluted in RNase-free water.
Quality was determined using NanoDrop (Type ND-1000, Wilm-
ington, USA) to measure 260/280 and 260/230 ratios. When ratios
were >1.9 and >1.7, respectively, the RNA was used for further
experiments.
DENDRITIC CELL CULTURE AND IMMUNOPHENOTYPING
Peripheral blood mononuclear cells (PBMCs) were isolated from
a fresh buffy coat (Sanquin blood bank North West, Amsterdam,
The Netherlands). These were obtained from healthy volunteers
that were HLA-A2 positive to obtain HLA-A2 positive PBMCs
matched with HLA-A2 positive cell lines. The PBMCs were isolated
by density gradient centrifugation using Ficoll. The monocytes
and lymphocytes were then separated by a density separation gra-
dient as previously described (Milano et al., 2007). The monocytes
were cultured in 24 wells plates (Greiner Bio-one, Alphen aan de
Rijn, The Netherlands) at a density of 5× 105 cells/ml in Cell-
Gro medium (CellGenix, Freiburg, Germany) supplemented with
800 U/ml IL-4 and 1000 IU/ml GM-CSF. At day 3, the immature
DCs were stimulated for 3 days with 5µg/ml monophosphoryl
lipid A (MPLA) (Invivogen, San Diego, USA) and 1000 IE/ml
IFN-γ, to obtain mature DCs, which were harvested and used
for stimulation of T cells as described before (ten Brinke et al.,
2007). Mature DCs were then incubated with 0 or 50µM nano-
curcumin, and then harvested after 48 h to evaluate the effect
of nano-curcumin on their immunophenotype by FACS analysis
as described previously (Milano et al., 2007). Briefly, DCs were
washed and incubated with primary anti-human antibody for
CD80, CD86, and CCR7 or isotype control in PBA (PBS contain-
ing 0.5% sodium azide). After 30 min of incubation on ice in the
dark, the cells were washed, re-suspended in PBA and analyzed on
a FACSCalibur (BD Biosciences). The data were analyzed by using
FlowJo software (Tree Star, Inc., Ashland, OR, USA). Supernatants
were as well collected to measure the effect of nano-curcumin on
cytokine levels performing CBA, as described below.
T CELL CULTURES AND IMMUNOPHENOTYPING
T lymphocytes were isolated from PBMC obtained from buffy
coats. PBMC were isolated by centrifugation on Ficoll (GE Health-
care Bio-Sciences) and the T cell fraction was immediately cryop-
reserved. On the day of the experiment, T cells were thawed and
cultured in RPMI 1640 (Invitrogen, NY, USA) supplemented with
10% FCS (Invitrogen). The T cell Activation/Expansion kit (Mil-
tenyi Biotec, Bergisch Gladbach, Germany) was used to activate
the T cells. Briefly, cells were incubated with anti-biotin MAC-
SiBead particles loaded with CD2, CD3, and CD28 antibodies,
using one loaded anti-biotin particle per two T cells, for 48 h at 37
°C. Resting or activated T cells were incubated with 0 or 50µM
nano-curcumin, and then harvested after 48 h to evaluate the effect
of nano-curcumin on their immunophenotype by FACS analysis
as previously described (Milano et al., 2007). Briefly, either rest-
ing or activated T cells were washed and incubated with primary
anti-human antibody for CD4, CD8, or isotype control in PBA
(PBS containing 0.5% sodium azide). After 30 min of incubation
on ice in the dark, the cells were washed, re-suspended in PBA
and analyzed on a FACSCalibur (BD Biosciences). The data were
analyzed by using FlowJo software (Tree Star, Inc., Ashland, OR,
USA). Supernatants were as well collected to measure the effect of
nano-curcumin on cytokine levels performing CBA, as described
below.
TRANSFECTION OF DC WITH TUMOR RNA AND CO-INCUBATION WITH
T CELLS
Mature DCs were harvested at day 6 of culture and after washing
they were electroporated using the Amaxa cell line Nucleofector
Kit V (Amaxa GmbH, Germany). DCs were mixed with Nucle-
ofector transfection solution V and 4µg of total RNA of OE19
or of OE33 or HET-1A cells. The program U16 of the Amaxa
transfection device was used to electroporate the cells. After this,
electroporated DCs were co-cultured with T lymphocytes at a ratio
of 1:4 in a 24 wells plate. After 1 week the T cells were harvested
and again co-cultured with freshly electroporated DCs for a sec-
ond stimulation. The different populations of T cells, namely CTLs
specific for the different cell line antigens, were used in the cytotox-
icity assay to determine their killing capacity against EAC cancer
cell lines.
EFFECT OF DC-MEDIATED T CELL RESPONSES AND NANO-CURCUMIN
TREATMENT ON CELL LYSIS OF TUMOR CELLS
The OE19, OE33, and HET-1A cell lines were pre-treated with
0 or 50µM nano-curcumin for 48 h. Subsequently, 10,000 tar-
get cells were harvested, washed, and co-incubated with different
amount of effector cells i.e., the above mentioned HLA-matched
specific CTLs that were stimulated with tumor RNA electropo-
rated DCs. DC and CTLs were co-cultured at an effector:target
ratio of 10:1 to 0,625:1 in 100µl of medium in a 96 wells plate
for 4 h at 37 °C. The percentage of cytotoxicity was measured by
using CytoTox 96 Non-Radioactive Cytotoxicity assay (Promega,
Madison, USA) following the manufacturer’s instructions and as
previously described (Milano et al., 2010). This assay quantitatively
measures lactate dehydrogenase (LDH), which is a stable cytoso-
lic enzyme released upon cell lysis. The released LDH in culture
supernatants is measured with a 30-min coupled enzymatic assay,
which results in the conversion of a tetrazolium salt (INT) into
a red formazan product. The amount of color is proportional to
the number of lysed cells. Visible wavelength absorbance data was
collected using a multi-well scanning spectrophotometer (ELISA
reader). The percentage of specific cytotoxicity was calculated
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using the formula: % cytotoxicity= (Experimental− Effector
Spontaneous−Target Spontaneous)/(Target Maximum−Target
Spontaneous)× 100.
CBA ASSAY
Supernatant collected from the cytotoxicity assays, and from
the cultures of DC, T cells and the EAC cell lines, untreated
or treated with nano-curcumin were analyzed for the simul-
taneous measurement of different pro- and anti-inflammatory
cytokines using the cytometric bead enzyme-linked immunosor-
bent assay systems (CBA, BD Biosciences). Specifically, the Human
Th1/Th2 cytokines kit and the Human Inflammatory kit were used
according to the manufacturer’s protocol, as previously described
(Milano et al., 2008).
STATISTICS
Data is represented as mean± SD. Comparison between groups
was carried out with Student’s t test. Values of P < 0.05 were con-
sidered as statistically significant. Asterisks indicate the level of
significance. All the experiments were carried out at least 3 times
(n= 3) with 2–4 technical replicate.
RESULTS
NANO-CURCUMIN UPTAKE ASSAY IN ESOPHAGEAL
ADENOCARCINOMA CELL LINES
To confirm that the structural changes in the preparation of this
nano-curcumin, do not affect its cellular uptake in esophageal cell
lines, we monitored its intracellular accumulation using CLSM
coupled to an inverted microscope (Olympus IX81, Japan). In
Figure 1 it is shown that after 1 h of incubation with 50µM nano-
curcumin, all the cell lines show a green signal, which increased
after 2 and 4 h, as compared to the negative untreated cells. At 6 h
the fluorescent signal of nano-curcumin decrease and at 48 h it
could not be visualized anymore by fluorescent microscopy. Our
results are in line with previous findings, where it was shown that
once taken up by cells, nano-curcumin is rapidly (within 7 h)
metabolized and becomes invisible after 48 h (Bisht et al., 2007;
Kunwar et al., 2008; Mathew et al., 2012). No major differences
were observed between the esophageal cancer (OE33 and OE19)
and normal (HET-1A) cell lines.
EFFECT OF NANO-CURCUMIN ON CELL PROLIFERATION OF EAC CELL
LINES
The functional effect of nano-curcumin on cell proliferation of the
EAC cell lines, OE19, OE33, and the normal squamous cells, HET-
1A, was investigated using a BrdU incorporation assay. Figure 2A
shows that treatment of the cells with 50µM nano-curcumin for
48 h, significantly decreased cell proliferation in the EAC cell lines
OE19 and OE33, but not in the normal esophageal squamous cell
line HET-1A, indicating that nano-curcumin selectively affects
the proliferation of cancer cells leaving the normal squamous
epithelial cells unaffected.
EFFECT OF NANO-CURCUMIN ON APOPTOSIS OF EAC CELL LINES
To test whether the inhibition of proliferation correspond to an
increase in apoptosis, we set out to investigate if the apoptotic sig-
naling pathways are affected after treatment with nano-curcumin.
FIGURE 1 | Uptake of nano-curcumin in EAC cell lines compared to
normal esophageal cell lines. Fluorescence microscopy analysis shows
that nano-curcumin, which is green autofluorescent is rapidly (within 1 h)
taken up by cells. The uptake seems to increase with time and it is still
observed after 6 h. Micrographic pictures are representative of three
independent experiments.
By performing Western blot on the lysates of the cell lines, we
could not detect a significant up-regulation of cleaved caspase-3
(the activated form of caspase-3) nor a significant decreasing levels
of procaspase-9 after treatment with nano-curcumin, as shown by
the densitometry of the western blots indicating that it does not
induce apoptosis in these cell lines (Figures 2B,C). Levels of several
other pro- and anti-apoptotic proteins and a Nicoletti apoptosis
assay confirmed these findings (data not shown).
EFFECT OF NANO-CURCUMIN ON THE IMMUNOPHENOTYPE, CYTOKINE
PRODUCTION AND APOPTOSIS OF DCs AND T CELLS
In previous studies it was shown that curcumin negatively affects
the immunophenotype of DCs (Kim et al., 2005). To determine
whether nano-curcumin has detrimental effects on cells of the
immune system, we first studied the changes in the immunophe-
notype, cytokine profile and apoptosis level of DCs before and
after exposure to nano-curcumin. Expression levels of CD80
and CCR7 in DCs did not change before and after exposure to
nano-curcumin. Thus unlike previous reports on free curcumin,
nano-curcumin leaves the functional phenotype of DCs intact
(Figure 3A). Also, we observed that nano-curcumin significantly
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FIGURE 2 | Nano-curcumin inhibits cell proliferation and does not induce
apoptosis in EAC cell lines. (A) BrdU assay results show that treatment of
the EAC cell lines OE33 and OE19 with 50µM nano-curcumin (NC) induces a
significant decrease in cell proliferation. This is not the case for the normal
esophageal cell line HET-1A (student’s two tailed paired t test, *P <0.05,
**P < 0.01, n=3). (B,C)Western blot analysis to check levels of cleaved
caspase-3 and procaspase-9 shows that treatment of the EAC cell lines OE33
and OE19 with 50µM nano-curcumin does not affect the levels of cleaved
caspase-3 and procaspase-9. This is as well shown by densitometry data
showing the ratio of cleaved caspase-3 and procaspase-9 to the loading
control β-actin using Image J software (student’s two tailed paired t test,
n=3). Gels are representative of three independent experiments.
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FIGURE 3 | Nano-curcumin does not interfere with the function of
dendritic cells (DC), and increases expression of the co-stimulatory
molecule CD86. (A) Fluorescence activated cell sorting (FACS) analysis
shows that nano-curcumin does not change the expression of CD80 and
CCR7 in DC, but it does significantly increase the expression of CD86 on DCs
(student’s two tailed paired t test, *P <0.05, n=4). (B) Cytometric bead array
show that nano-curcumin does not change the cytokine production profile of
the DCs (student’s two tailed paired t test, n=3). (C) Flow cytometric
detection of annexin V (AV) and propidium iodide (PI) shows that
nano-curcumin does not induce apoptosis in DCs. Data are showing the
percentage of early apoptotic (annexin V+/PI−) and late apoptotic/necrotic
(annexin V+/PI+) populations (student’s two tailed paired t test, n=3).
increased the expression level of the co-stimulatory molecule
CD86 in DCs, indicating that it drives DCs to mature toward a
functional phenotype. We also observed that nano-curcumin has
no effects on the cytokine profile of these DCs (Figure 3B) and
that it did not induce apoptosis of DCs (Figure 3C).
Next, we investigated the effect of nano-curcumin on T cell
phenotype and function. We showed that nano-curcumin did not
change the phenotype of resting nor activated T cells as observed
by unchanged expression levels of CD4 and CD8 after treatment
(Figures 4A,D). In activated T cells, nano-curcumin significantly
decreased the amount of early apoptotic cells (Figure 4F) but
had no effect on resting T cells (Figure 4C). Accordingly, nano-
curcumin did not affect the production of cytokines of resting
T cells (Figure 4B), but it did significantly reduce the secretion
of TNF-α, IL-8, IL-6, IL-10, and IL-1β in activated T cells. This
indicates that nano-curcumin modulates the cytokine profile of
activated T cells toward a profile that negatively affects tumor cell
growth and migration (Figure 4E).
From our results we can conclude that nano-curcumin has no
negative effects on the immune-profile of both DCs and T cells
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FIGURE 4 | Effect of nano-curcumin on resting and activatedT cells. (A)
As measured by FACS, the CD4/CD8 ratio of resting T cells does not change
after nano-curcumin treatment (student’s two tailed paired t test, P >0,05,
n=3). (B) Nano-curcumin does not affect the release of TNF-α and IL-8 of
resting T cells (student’s two tailed paired t test, P >0,05, n=3). (C)The
fractions of early apoptotic (annexin V+/PI−) and late apoptotic/necrotic
(annexin V+/PI+) populations as measured by FACS analysis show no
difference in apoptosis between resting T cells that were left untreated or
treated with nano-curcumin (student’s two tailed paired t test, *P <0.05,
n=3). (D) As measured by FACS, the CD4/CD8 ratio of activated T cells
does not change after nano-curcumin treatment (student’s two tailed paired
t test, P >0,05, n=3). (E) Nano-curcumin reduces the production of TNF-α,
IL-8, IL-6, IL-10, IL-1β in activated T cells (student’s two tailed paired t test,
**P < 0.01, n=3). (F)There is a decrease of the early apoptotic (AV+/PI−)
fraction of the activated T cells after treatment with nano-curcumin
(student’s two tailed paired t test, *P <0.05, n=3).
and does not negatively affect their function. Instead, these results
for the first time show that nano-curcumin supports the function
of DCs and T cells in inducing anti-tumor immune responses.
EFFECT OF NANO-CURCUMIN ON DC-MEDIATED T CELL-INDUCED
CYTOTOXICITY
To determine whether nano-curcumin enhances DC-mediated T
cell induced cytotoxicity, we tested the effects of nano-curcumin
pre-treatment of EAC cell lines in CTL cytotoxicity assays.
Through electroporation DCs were loaded with the RNA of OE19
and OE33 cell lines. Specific anti-cancer CTL populations were
obtained through stimulating T cells with the RNA loaded DCs.
Using an effector (CTLs) to target (EAC cells) ratio of 10:1, in
OE19 and OE33 cells, the CTLs induced a mean cell lysis of 6.4 and
4.06%, respectively (Figure 5A). Pre-treatment of the tumor cells
with 50µM nano-curcumin significantly increased the mean cell
lysis to 15 and 13%, respectively. This indicates that pre-treatment
with nano-curcumin sensitizes EAC cells to specific CTL-induced
cytotoxicity. In a similar experiment we found no cytotoxicity
against the normal esophageal cell line HET-1A (Figure 5A). We
also evaluated the production of cytokines after 4 h of incubation
of the EAC target cells with the effector cytotoxic T cells with and
without pre-treatment of nano-curcumin. We found that in the co-
culture of OE19 with CTLs there were no changes in the cytokine
production profile (Figure 5C). When CTLs where incubated
with OE33, however, nano-curcumin pre-treatment significantly
increased the production of IFN-γ, while the production of IL-8
significantly decreased. No significant changes were observed for
TNF-α and IL-2 (Figure 5B). This is interesting considering that
IL-8 was found to be highly expressed in OE33 and OE19 (data
not shown) and was previously reported to be highly expressed
in EAC (Milano et al., 2008). Reduced levels of IL-8 may reduce
the migratory functions of esophageal cancer cells, while higher
levels of IFN-γ support the function of DCs and T cells, again
indicating that nano-curcumin seems to enhance the function of
the immune system against tumor cells.
DISCUSSION
Curcumin is a natural substance that is known to have anti-
carcinogenic and anti-inflammatory effects against several types of
cancers (Kunnumakkara et al., 2009; O’Sullivan-Coyne et al., 2009;
Jutooru et al., 2010; Yallapu et al., 2012). A disadvantage of free
curcumin is that it is highly hydrophobic and is poorly absorbed
after oral administration (Li et al., 2005). Due to this low biolog-
ical activity, high doses of free curcumin are necessary to obtain
significant responses (Bhawana et al., 2011). Various curcumin
nano-formulations have been developed to improve its solubility,
bioavailability, and pharmacokinetic properties, allowing easier
in vitro and preclinical in vivo testing. Sasaki et al. (2011), recently
formulated an innovative colloid-based preparation of curcumin
named Theracurmin (nano-curcumin) and demonstrated its oral
bioavailability and safety in healthy subjects. The toxicity of this
type of nano-curcumin is currently being tested in a clinical trial
in patients with advanced malignancies (ClinicalTrials.gov identi-
fier: NCT01201694). So far, besides one single event of diarrhea,
no adverse events have been recorded, again indicating that this
form of nano-curcumin is safe and well tolerated (Kanai et al.,
2012).
Although these studies deem nano-curcumin as a safe sub-
stance, its biological function, has yet to be confirmed. Because
other forms of nano-curcumin have the same biological effects as
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FIGURE 5 | Nano-curcumin enhancesT cell mediated cancer cell lysis. (A)
Cytotoxicity assay showing different E:T ratios of OE19 and OE33 co-culture
with CTLs. Cell lysis induced by CTLs at the E:T ratio of 10:1 is 6.4 and 4.06%,
respectively. Pre-treatment with nano-curcumin, significantly increases the
CTLs induced lysis to 15 and 13% respectively (E=effector=CTLs,
T= target=EAC cells; student’s two tailed paired t test, *P <0.05, n=3). At
the E:T ratio of 10:1 there is no cytotoxicity induced by CTLs on the HET-1A
cells, which also does not change after nano-curcumin treatment. (B)The
cytokine profile as measured in the supernatant after the cytotoxicity assay
shows that in the co-culture of CTLs and OE33, pre-treatment with
nano-curcumin increases IFN-γ production and decreases the production of
IL-8 (student’s two tailed paired t test, *P < 0.05, n=3). (C) In the supernatant
of the co-culture of OE19 cells with CTLs, pre-treatment with nano-curcumin
did not change the cytokine profile (student’s two tailed paired t test, n=3).
free curcumin in pancreatic and prostate cancer (Bisht et al., 2007;
Yallapu et al., 2012), we set out to demonstrate that nano-curcumin
retains the anti-carcinogenic and anti-inflammatory properties
attributed to free curcumin, and thus be used as a possible adjuvant
for the treatment of EAC.
We show that nano-curcumin has a direct anti-proliferative
effect on EAC cell lines, in line with previous results showing
that free curcumin decreases the proliferation and survival of
esophageal cancer cells (Subramaniam et al., 2012). It is worth
mentioning the specific anti-proliferative effect of nano-curcumin
toward cancer but not normal cell lines. This characteristic is not
due to differential cellular uptake, as we have proved that intra-
cellular accumulation of nano-curcumin is equal in both types of
cell lines. Instead, it could be speculated that divergences in sig-
naling pathways between cancer and normal cells account for the
selective proliferative effects of the nano-curcumin. For example,
the signaling pathways affected by nano-curcumin, might be more
activated in esophageal cancer cells as compared to normal cells,
rendering the cancer cells more susceptible to the effects of nano-
curcumin. Indeed, one of the most important pathways involved
in cellular proliferation and aberrantly activated in cancer stem
cells, the Notch signaling pathway, has been shown to be inhibited
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by free curcumin in esophageal cell lines (Subramaniam et al.,
2012). Therefore, it is tempting to speculate that by inhibiting this
pathway, nano-curcumin might selectively suppress proliferation
of the EAC cell lines.
Although nano-curcumin has been demonstrated to also
induce apoptosis in a variety of cells including pancreatic can-
cer cells (Sahu et al., 2009; Jutooru et al., 2010), we did not observe
an effect on apoptosis of esophageal cell lines. Several mech-
anisms for curcumin-mediated apoptosis have been suggested.
Shankar et al. (2007), for instance demonstrated that curcumin
upregulates the expression of pro-apoptotic members of the Bcl-
2 family like Bax and Bak and inhibits the anti-apoptotic Bcl-2
proteins, such as Bcl-XL and Bcl-2. Also curcumin was found to
affect several caspases such as caspase-8 (Anto et al., 2002). We
tested the levels of the above mentioned pro- and anti-apoptotic
pathways, including Bcl-2 and Bcl-XLs, but could not see any
significant change in any of the apoptotic pathways after treat-
ing the EAC cells with nano-curcumin. The discrepancy between
our results and the above mentioned studies could be attrib-
uted to differences in signaling pathways between the different
cancer cells or to the intrinsic resistance of EAC cells to apop-
tosis, as it has been previously reported (O’Sullivan-Coyne et al.,
2009).
Another level at which Theracurmin exerts its anti-carcinogenic
effect on esophageal tumor cells is by increasing their susceptibil-
ity to be killed by cytotoxic T cells. CTLs were stimulated ex vivo
with DCs loaded with tumor-derived RNA, and were used in cyto-
toxic assays to determine their ability to recognize and lyse EAC
cells. We found that nano-curcumin has a sensitizing effect on
DC-mediated T cell cytotoxicity by increasing cell lysis on EAC
cells. We also observed that nano-curcumin increased the IFN-γ
secretion and decreased the TNF-α secretion in the co-culture of
OE33 with CTLs and nano-curcumin.
One earlier report showed that curcumin has a detrimental
effect on the immune-phenotype of DCs (Kim et al., 2005). In
our study, however, we found that neither DCs nor T cells are
negatively affected by nano-curcumin. Instead, we found that
nano-curcumin up-regulated the expression of the co-stimulatory
molecule CD86 and reduced the levels of anti-inflammatory
cytokines in activated T cells, asserting the role of nano-curcumin
in anti-inflammatory processes. This is as well in line with previ-
ous findings were it was shown that nano-curcumin reduces the
levels of multiple pro-inflammatory cytokines (Bisht et al., 2007;
Anand et al., 2010).
It has become clear that combining anti-cancer treatments
potentiates the effect of anti-cancer agents (Vanneman and Dra-
noff, 2012). For instance, the combination of curcumin with
Gemcitabine for the treatment of pancreatic cancer, leads to
increased apoptosis in vitro and reduced cell proliferation in vivo
(Buckanovich et al., 2008; Dhillon et al., 2008).
One important direction in the field of oncology is to com-
bine conventional (chemo) therapeutical agents with strategies
that enhance the immune system (Ramakrishnan et al., 2010). Our
results confirm that nano-curcumin not only directly affects EAC
cancer cell proliferation but also potentiates the immune response
to the tumor cells, making this compound extremely attractive to
be used in immune combinatorial therapies for EAC.
However, further in vivo evaluations are warranted to confirm
its efficacy as a novel and more efficacious adjuvant therapy for
this aggressive cancer.
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